• ▶ polycystic ovary syndrome • ▶ metabolic syndrome • ▶ lipid accumulation product Lipid Accumulation Product is Related to Metabolic Syndrome in Women with Polycystic Ovary Syndrome are exposed to risk factors at a younger age [ 9 ] . Early and accurate identifi cation of high-risk individuals for MS could be important to predict and prevent CVD and type 2 diabetes. There is, therefore, an urgent need to develop a simple, accurate and economic predictor for MS in PCOS. The lipid accumulation product (LAP), which was fi rst described by Kahn [ 10 ] , is based on a combination of waist circumference (WC) and serum triglycerides (TG) and serves as a simple index for lipid over accumulation in adults. High levels of LAP are associated with CVD, impaired glucose tolerance (IGT) and type 2 diabetes [ 11 , 12 ] . In healthy population, LAP is a powerful marker of MS [ 13 , 14 ] , however, to the best of our knowledge, there is currently limited research on the relationship between LAP and MS in women with PCOS. Thus, we aim to investigate the ability of LAP to identify MS in PCOS patients. . It is characterized by hyperandrogenemia, chronic anovulation, and polycystic ovary morphology [ 2 , 3 ] .The etiology of PCOS is still not very clear, however, previous studies have shown that insulin resistance (IR) and central obesity are key pathological factors of PCOS [ 4 , 5 ] . PCOS is not only the reproductive endocrine disease, but also metabolic disorder. Patients with PCOS are often accompanied by metabolic abnormalities, such as dyslipidemia, obesity, and glucose intolerance, which are also components of the metabolic syndrome (MS) [ 6 ] . MS is a cluster of metabolic disorders associated with increased risk of cardiovascular disease (CVD), and central or abdominal obesity is considered a fundamental pathology for the MS. Many of the anthropometric and metabolic abnormalities of PCOS overlap with components of MS, and PCOS patients are at increased risk of having MS [ 7 ] . Adults with MS are at a greater risk of developing CVD [ 8 ] . PCOS women with MS may be at even greater risk for CVD because they 
Introduction

▼
Polycystic ovary syndrome (PCOS) is one of the most common female endocrine disorders with a prevalence of 5-10 % in women of reproductive age [ 1 ] . It is characterized by hyperandrogenemia, chronic anovulation, and polycystic ovary morphology [ 2 , 3 ] .The etiology of PCOS is still not very clear, however, previous studies have shown that insulin resistance (IR) and central obesity are key pathological factors of PCOS [ 4 , 5 ] . PCOS is not only the reproductive endocrine disease, but also metabolic disorder. Patients with PCOS are often accompanied by metabolic abnormalities, such as dyslipidemia, obesity, and glucose intolerance, which are also components of the metabolic syndrome (MS) [ 6 ] . MS is a cluster of metabolic disorders associated with increased risk of cardiovascular disease (CVD), and central or abdominal obesity is considered a fundamental pathology for the MS. Many of the anthropometric and metabolic abnormalities of PCOS overlap with components of MS, and PCOS patients are at increased risk of having MS [ 7 ] . Adults with MS are at a greater risk of developing CVD [ 8 ] . PCOS women with MS may be at even greater risk for CVD because they 
Research methods
All PCOS patients underwent anthropometric measurements, including weight, height, waist circumferences (WC), Systolic blood pressure (SBP), Diastolic blood pressure (DBP) and the body mass index (BMI) was calculated. Fasting blood samples were obtained from PCOS patients in order to measure luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol (E2), total testosterone (T), fasting glucose (FBG), fasting insulin (FINS), serum triglycerides (TG), total cholesterol (TC), high density lipoprotein (HDL-C) and low density lipoprotein (LDL-C) levels.
A standard 75-g oral glucose tolerance test was performed for the evaluation of the glucose tolerance status. Insulin sensitivity was assessed by homeostasis model assessment of insulin resist-
LAP was calculated using the formula [waist (cm) − 58] × triglyceride concentration (mmol/l), as previously reported [ 10 ] .
Statistical analysis
Statistical analysis was performed by using SPSS15. The results of LAP, WC, BMI and TG ROC curve analysis showed that each marker is a signifi cant discriminator for MS in PCOS women. The largest AUC was obtained with LAP, indicating that LAP was superior for estimating the MS of PCOS patients in this study ( • ▶ Table 2 ). From the ROC curve analysis, the optimal cutoff points of LAP to predict MS in PCOS were 54.2 (93.3 % sensitivity, 96.7 % specifi city, • ▶ Fig. 1 ). Table 2 The area under ROC for LAP, WC, BMI and TG to identify MS in PCOS women. PCOS is a condition associated with increased risk for cardiovascular disturbances [ 16 , 17 ] . PCOS women are at increased risk of having MS, and the prevalence of MS in PCOS patients varies among diff erent ethnicities depends on the defi nition used [ 18 -20 ] . In this study, the prevalence of MS, as diagnosed according to IDF criteria, was 42.8 % in the studied Chinese PCOS patients. MS itself is a risk for type 2 diabetes and CVD, so early and accurate identifi cation of high-risk individuals for MS is of great importance [ 21 ] . Previous studies have evaluated enlarged WC and elevated TG in diff erent populations as a surrogate marker of cardiovascular risk. LAP, an ordinal scale combining WC and TG, could be associated to a dysfunctional and highly lipolytic adipose tissue that is a central abnormality behind MS, CVD and type 2 diabetes [ 22 ] . The population-based United States' National Health and Nutrition Examination Survey (NHANES III) concluded that LAP was superior to BMI for recognizing CVD risk and diabetes [ 10 , 11 ] . In the present study, PCOS women with MS had higher LAP levels in comparison to those without MS. This indicates that high LAP levels are associated with MS in PCOS women. IR plays a central role in both the reproductive and metabolic disturbances observed in women with PCOS [ 23 ] . In our study, PCOS women with MS had signifi cantly increased HOMA-IR compared to those without MS. Meantime, we showed that LAP was significantly correlated with HOMA-IR, indicating that LAP may be useful to precociously screen a subset of young women who are susceptible to the development of IR-related comorbidities, including MS, diabetes and CVD. In addition, we demonstrated LAP was highly correlated with WC, SBP, DBP, FBG, PBG, TG and HDL-C, which were components of MS. Therefore, LAP is related to MS and can serves as a reliable marker of MS in PCOS women [ 24 ] . Both WC and BMI are shown to be good predictors of the presence of MS [ 25 ] . TG, also, is a reliable predictor for these cardiometabolic syndromes. In our study, ROC analysis showed that LAP, WC, BMI and TG were signifi cant discriminators for MS in PCOS women. However, the largest AUC was obtained with LAP, indicating that LAP was superior to WC, BMI and TG for predicting MS of PCOS patients. In addition, ROC curve showed that LAP ≥ 54.2 had adequate sensitivity and specifi city for detecting a state of MS in PCOS women. The high sensitivity and specifi city of LAP detected in ROC curve analysis indicate that LAP might be a useful marker to predict MS in PCOS women. The early identifi cation of PCOS women with MS and introduction of therapeutic interventions may help delay the progression to CVD and T2DM.
Markers
Limitations of the present study are the small sample size and the ethnic origin, Therefore, further research should be undertaken in larger sample sizes and diff erent ethnic groups.
In conclusion, our results show that LAP, an easily obtainable measure, has a strong and reliable diagnostic accuracy for MS in PCOS women. Early and accurate identifi cation of high-risk individuals for MS will allow introduction of therapeutic interventions to prevent CVD and type 2 diabetes.
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